WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New ATC

List of new ATC codes decided at the latest meetings of the WHO International Working Group for Drug Statistics Methodology. Comments or objections to the ATC codes should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology within the deadline. If no objections are received, the new ATC codes will be considered final and included in the ATC/DDD Index. The year of implementation in the ATC/DDD Index is given in the list.

ATC codeATC level name (INN/generic name)Deadline for objection to temporary code Implementation in the ATC/DDD index
A10BD26metformin and lobeglitazone01.02.20202021
A10BG04lobeglitazone01.02.20202021
A10BH08teneligliptin01.02.20202021
A10BK07luseogliflozin01.02.20202021
A16AX16givosiran01.02.20202021
A16AX30sodium benzoate and sodium phenylacetate01.02.20202021
B03AD05ferrous gluconate01.02.20202021
B05XA18zinc sulfate01.02.20202021
B06AX02betibeglogene autotemcel01.02.20202021
C09BX05ramipril and bisoprolol01.02.20202021
C10AX16inclisiran01.02.20202021
C10BX18atorvastatin, amlodipine and ramipril01.02.20202021
D11AX26caffeine01.02.20202021
G02CX05bremelanotide01.02.20202021
H01AC07somapacitan01.02.20202021
H02CA03ketoconazole 1)01.02.20202021
H05AA04abaloparatide01.02.20202021
H05BX05calcifediol 2) 01.02.20202021
J01DH56imipenem, cilastatin and relebactam01.02.20202021
J01DI04cefiderocol01.02.20202021
J01MA24levonadifloxacin01.02.20202021
J05AX28bulevirtide01.02.20202021
J05AX29fostemsavir01.02.20202021
J07BX02ebola (vesicular stomatitis virus vector live attenuated)01.02.20202021
L01XC34moxetumomab pasudotox01.02.20202021
L01XC35tafasitamab01.02.20202021
L01XC36enfortumab vedotin01.02.20202021
L01XC37polatuzumab vedotin 01.02.20202021
L01XC38isatuximab01.02.20202021
L01XC39belantamab mafodotin01.02.20202021
L01XC40dostarlimab01.02.20202021
L01XX70axicabtagene ciloleucel01.02.20202021
L01XX71tisagenlecleucel01.02.20202021
L04AA45filgotinib01.02.20202021
L04AA46itacitinib01.02.20202021
L04AC19satralizumab01.02.20202021
M02AA29esflurbiprofen01.02.20202021
M09AX08golodirsen01.02.20202021
M09AX09onasemnogene abeparvovec01.02.20202021
M09AX10risdiplam01.02.20202021
N01BB59bupivacaine and meloxicam01.02.20202021
N02BG11mirogabalin01.02.20202021
N04CX01istradefylline01.02.20202021
N05CD15nimetazepam01.02.20202021
R07AX32ivacaftor, tezacaftor and elexacaftor01.02.20202021
S01GA07brimonidine01.02.20202021
S01LA07abicipar pegol01.02.20202021
1) Oral formulations only indicated in treatment of Cushing’s syndrome
2) Oral formulations only indicated in treatment of renal secondary hyperparathyroidism

New ATC level codes (other than 5th levels)

ATC codeATC level nameDeadline for objection to temporary alterations Implementation in ATC/DDD index
N04COther antiparkinson drugs01.02.20202021
N04CXOther antiparkinson drugs01.02.20202021

Last updated: 2019-11-28